Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.68 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.68 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4243436 | 0.91 | KCNA5 (0.57) | KCNA5KCNA3KCNK3SMN1; SMN2KDM4E | |
| SCHEMBL5444524 | 0.84 | KCNA5 (0.66) | KCNA5KCNA3KCNK3SMN1; SMN2KDM4E | |
| SCHEMBL498107 | 0.81 | KCNA5 (1.00) | KCNA5KCNA3KCNK3HTTLMNA | |
| SCHEMBL2212471 | 0.81 | KCNA5 (1.00) | KCNA5KCNA3KCNK3HTTLMNA | |
| SCHEMBL498106 | 0.81 | KCNA5 (1.00) | KCNA5KCNA3KCNK3HTTLMNA | |
| SCHEMBL4232259 | 0.81 | KCNA5 (0.42) | KCNA5KCNA3KDM4EPOLBNPC1 | |
| SCHEMBL4225702 | 0.81 | KCNA5 (0.42) | KCNA5KCNA3KDM4EPOLBNPC1 | |
| SCHEMBL2211818 | 0.79 | KCNA5 (0.49) | KCNA5KCNA3KCNK3SMN1; SMN2KDM4E | |
| SCHEMBL12434425 | 0.75 | KCNA5 (0.88) | KCNA5KCNA3KCNK3SMN1; SMN2TAS1R3 | |
| SCHEMBL12434426 | 0.75 | KCNA5 (0.88) | KCNA5KCNA3KCNK3SMN1; SMN2TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043091-A1 | Kv1.5-BLOCKER FOR THE SELECTIVE INCREASE OF ATRIAL CONTRACTILITY AND TREATMENT OF CARDIAC INSUFFICIENCY | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043091-A1 | Kv1.5-BLOCKER FOR THE SELECTIVE INCREASE OF ATRIAL CONTRACTILITY AND TREATMENT OF CARDIAC INSUFFICIENCY | KCNJ2, KCNH2, KCNK5 | KCNA5 4/4885KCNA3 24/4885KCNK3 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.